Context Therapeutics doses first patient in Phase 1 trial of CTIM-76 for CLDN6-positive cancers

Context Therapeutics Inc.

First patient dosed in Phase 1 open-label trial of CTIM-76 (CLDN6 x CD3 bispecific antibody).
Trial targets CLDN6-positive advanced/metastatic ovarian, endometrial, and testicular cancers.
Study expected to enroll up to 70 patients; initial data anticipated first half of 2026.
CEO Martin Lehr highlights the milestone as key pipeline advancement.
Company presented at SITC 2024 supporting first-in-human dose selection.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.